DPI 3290

Drug Profile

DPI 3290

Alternative Names: ORG-41793

Latest Information Update: 13 Nov 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Enhance Biotech
  • Class Benzamides; Opioid analgesics; Piperazines
  • Mechanism of Action Opioid delta receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 29 Dec 2004 Ardent Pharmaceuticals has been acquired by Enhance Biotech
  • 17 Jul 2001 Phase-I clinical trials for Pain in USA (Sublingual)
  • 17 Jul 2001 Phase-II clinical trials for Pain in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top